News

Director/PDMR Shareholding
Director/PDMR Shareholding
August 14, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 13 August 2018, it purchased 500,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 58,259,431 equivalent to 19.74% of Proteome Sciences' total issued share capital.

Director PDMR Shareholding
Director PDMR Shareholding
August 9, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 7 August 2018, it purchased 1,400,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 57,759,431 equivalent to 19.6% of Proteome Sciences' total issued share capital

Director/PDMR Shareholding
Director/PDMR Shareholding
August 2, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 1 August 2018, it purchased 328,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 56,359,431 equivalent to 19.09% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
August 1, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 27 July 2018, it purchased 525,000 ordinary shares and 118,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.49p and 3.5p respectively per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 56,031,431 equivalent to 18.98% of Proteome Sciences' total issued share capital.

Director/PDMR shareholding
Director/PDMR shareholding
July 28, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 25 July 2018, it purchased 171,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 2.85p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 55,388,431 equivalent to 18.76% of Proteome Sciences' total issued share capital.

 

Interim results for the six months ended 30 June 2018
Interim results for the six months ended 30 June 2018
July 24, 2018

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2018

Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:

“Performance during the first six months of 2018 was behind expectations, with recognised revenues from our services business still lagging committed work orders as we continue to build our customer base; TMT® revenues were ahead of the equivalent period in 2017.

Loan Agreement and Notice of Results
Loan Agreement and Notice of Results
July 3, 2018

Loan Agreement and Notice of Results

The Company announces that it has entered into an unsecured £1,000,000 loan facility agreement (“Loan Facility”) with Vulpes Lifesciences Fund (“Vulpes”) to be used for working capital purposes.

As announced at the time of the AGM on 30 May 2018, the Company has been in discussions with a number of larger shareholders who remain supportive and will provide non-dilutive funding should it be required to facilitate the evolution of the business. The Loan Facility will provide the Company with additional working capital while it continues to invest in growing its services business.  

 

AGM Statement and Result of AGM
AGM Statement and Result of AGM
May 30, 2018

At the AGM held earlier today the CEO, Jeremy Haigh, made a brief statement:  “As stated in our recent results, we expect 2018 to be a year of progress as we develop our biomarker services business and the market for TMT® strengthens.   Trading is broadly in line with expectations despite a characteristically slower first quarter, and the services business continues to demonstrate significant growth.   While the Company remains cash constrained, we have had discussions with a number of our larger shareholders who remain supportive and will provide non-dilutive funding should it be required to facilitate the evolution of the business.”

 

 

Annual Report and Financial Statements 31 December 2017
Annual Report and Financial Statements 31 December 2017
April 27, 2018

The Annual Report and Accounts for the year ended 31 December 2017, together with a notice of the Annual General Meeting is available to view on the Companies website www.proteomics.com and will be posted to shareholders imminently.

Preliminary Results 31 December 2017 andNotice of AGM
Preliminary Results 31 December 2017 andNotice of AGM
April 24, 2018

The Company is pleased to announce its audited results for the year ended 31 December 2017.